Ergoteles’s Enliven Therapeutics ELVN Stock Holding History

Ergoteles’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,887	Closed	-$249K	–	1336
2021 Q2	$249K	Buy	+7,887	New	+$245K	0.01%	1166

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ergoteles's ELVN Position: Q3 2021 in Review

Ergoteles sold out of Enliven Therapeutics (ELVN) in Q3 2021, closing a stake of 7,887 shares — an estimated $249K sold.

Ergoteles first reported a position in ELVN in Q2 2021 and held it in 1 quarter. The position peaked at $249K in Q2 2021. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2021.

Ergoteles reported no remaining Enliven Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 7,887 Enliven Therapeutics shares in Q3 2021, an estimated $249K.
Ergoteles first reported a position in Enliven Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Enliven Therapeutics position peaked at $249K in Q2 2021.
38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.